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Abstract
Background: Elevated level of reactive carbonyl species, such as methylglyoxal, triggers carbonyl stress and activates a
series of inflammatory responses leading to accelerated vascular damage. Edaravone is the active substance of a Japanese
medicine, which aids neurological recovery following acute brain ischemia and subsequent cerebral infarction. Our aim was
to test whether edaravone can exert a protective effect on the barrier properties of human brain endothelial cells (hCMEC/
D3 cell line) treated with methylglyoxal.
Methodology: Cell viability was monitored in real-time by impedance-based cell electronic sensing. The barrier function of
the monolayer was characterized by measurement of resistance and flux of permeability markers, and visualized by
immunohistochemistry for claudin-5 and b-catenin. Cell morphology was also examined by holographic phase imaging.
Principal Findings: Methylglyoxal exerted a time- and dose-dependent toxicity on cultured human brain endothelial cells: a
concentration of 600 mM resulted in about 50% toxicity, significantly reduced the integrity and increased the permeability
of the barrier. The cell morphology also changed dramatically: the area of cells decreased, their optical height significantly
increased. Edaravone (3 mM) provided a complete protection against the toxic effect of methylglyoxal. Co-administration of
edaravone restored cell viability, barrier integrity and functions of brain endothelial cells. Similar protection was obtained by
the well-known antiglycating molecule, aminoguanidine, our reference compound.
Conclusion: These results indicate for the first time that edaravone is protective in carbonyl stress induced barrier damage.
Our data may contribute to the development of compounds to treat brain endothelial dysfunction in carbonyl stress related
diseases.
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Introduction
Increased serum levels of reactive carbonyl species, such as
methylglyoxal, are present in several pathologies and cause
complications in severe conditions and diseases, like diabetes
mellitus [1,2], cardiovascular diseases [3,4], atherosclerosis [5],
hypertension [6], metabolic syndrome [7], obesity [8], psoriasis
[9], aging [10,11] Alzheimer’s disease [12] [13], dementias [14],
and other neurobiological diseases [15]. Methylglyoxal is a highly
reactive a-oxoaldehyde with strong oxidant and glycation prop-
erties [16]. Its immediate elimination by detoxification systems is
crucial [17]. Accumulated methylglyoxal reacts with proteins,
DNA and other biomolecules [18] causing inhibition of enzyme
activity [19], transcriptional activation [20], apoptosis [21]. The
end products of the reactions between methylgyoxal and free
amino groups of molecules are insoluble protease-resistant
polymers (advanced glycation end products AGE) [22]. Methyl-
glyoxal triggers carbonyl [18] and oxidative stress [23,24] and
activates a series of inflammatory responses leading to accelerated
vascular endothelial damage [25–27].
Based on data obtained on peripheral endothelial cells, the
effect of methylglyoxal on brain microvascular endothelium,
which forms the blood-brain barrier was also investigated
[25,28]. A concentration-dependent cell toxicity and barrier
dysfunction was recently described on a brain endothelial cell line
[28]. This study reported methylglyoxal-induced glycation of the
tight junction protein occludin in culture, as well as in brain
microvessels of diabetic rats, and a disturbed architectural
organization of zonula occludens-1 protein. Similar to other
cellular systems, methylglyoxal-treatment promoted carbonyl and
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oxidative stress in brain endothelial cells [28]. Methylglyoxal
induced mitochondrial apoptotic signaling: decreased mitochon-
drial membrane potential, activated caspases and perturbed the
cellular glutathione redox status [25]. These findings indicate that
methylglyoxal-induced carbonyl and oxidative stress may play an
important role in neurovascular pathology, and brain endothelium
can be an early and significant target site of methylglyoxal.
The prevention of methylglyoxal-induced injury is in the focus
of current research [29]. Aminoguanidine was the first drug
extensively studied, and attenuated the development of a range of
diabetic vascular complications both in vitro and in vivo. How-
ever, due to toxic side effects at high doses, it failed in clinical trials.
This compound is considered as a prototype for antiglycation
agents and used as a reference molecule in experiments [30].
Recently, a new promising agent, edaravone is investigated for its
beneficial effects on brain endothelial cells. Edaravone is a
neuroprotective free radical scavenger. It is the active substance
of a Japanese medicine, which helps neurological recovery
following acute brain and subsequent cerebral infarct [31,32].
To further reveal the mechanism of protection, brain microvessels
[33] and the blood-brain barrier [34] were investigated as
potential pharmaceutical targets of edaravone in animal models
of stroke. The effect of edaravone alone has been described on
barrier function: it promoted tight junction formation via
activation of sphingosin-1-phospate signaling pathway [35] and
down-regulation of interleukin-1b induced monocyte chemoat-
tractant protein-1 secretion [36] in human microvascular endo-
thelial cells. In a recent study, methylglyoxal-induced decrease in
cell viability and methylglyoxal enhanced cell injury by oxygen-
glucose deprivation were alleviated by pretreatment with edar-
avone in brain endothelial cells [37]. However, it remained
unanswered whether edaravone can also protect against methyl-
glyoxal-induced barrier dysfunction of brain endothelial mono-
layers.
The tight intercellular barrier maintaining low permeability is
the fundamental characteristic of brain endothelial cells [38].
Therefore, this study aimed to clarify the effect of edaravone
against methylglyoxal-induced barrier and morphological damage.
In the experiments the widely used human hCMEC/D3 brain
endothelial cell line [39], and new investigation methods, such as
impedance monitoring in multiwell plates and holographic phase
contrast imaging were used in addition to viability assays,
permeability tests and immunohistochemistry for junctional
proteins.
Materials and Methods
Ethics statement
All procedures involving experimental animals adhered to the
law (No. 105) and notification (No. 6) of the Japanese Govern-
ment, and were approved by the Laboratory Animal Care and
Use Committee of Fukuoka University. The details of the isolation
of primary brain endothelial cells from rats is described in Text S1.
Materials
All reagents were purchased from Sigma-Aldrich Ltd., Hun-
gary, unless otherwise indicated.
Cell Culture
Human hCMEC/D3 brain endothelial cell line [39,40] at
passage number #35 was used in the experiments. Cells were
plated on rat tail collagen-coated culture dishes (Orange Scientific,
Braine-l’Alleud, Belgium) or Transwell clear inserts (polyethylene
membrane, 0.4 mm pore size, 1.2 cm2 surface area, Corning Life
Sciences, Tewksbury, MA, USA) depending on the experiment
and cultured at 37uC, 5% CO2 in EBM-2 medium (Lonza, Basel,
Switzerland) containing 5% fetal bovine serum, hydrocortisone
(1.4 mM), 10 mM HEPES, gentamycin (50 mg/mL), acid ascorbic
(5 mg/mL), 1% chemically defined lipid concentrate, basic
fibroblast growth factor (1 ng/mL) (Roche, Basel, Switzerland).
Cells were seeded in culture dishes at a density of 2.56104 cells/
cm2 and the medium was changed every 3 days. At the first
change of medium, the medium was supplemented with 10 mM
lithium chloride [41]. When cells reached approximately 80–90%
of confluence in the dish, they were subcultured with 0.05%
trypsin-EDTA solution. For the cytotoxicity assays cells were
cultured in 96-well culture plates (Orange Scientific, Braine-
l’Alleud, Belgium). For real-time cell electronic sensing 96-well
plates with gold electrodes (E-plate 96, ACEA Biosciences, San
Diego, USA) were used. For permeability studies cells were
cultured on Transwell inserts.
Treatments
Human brain endothelial cells were treated with methylglyoxal
in the 100–1000 mM concentration range in EBM-2 medium
containing 10% fetal bovine serum, HEPES (10 mM) and
gentamycin (50 mg/mL). Edaravone was used in the 600–
3000 mM concentration range. Aminoguanidine, a well-known
antiglycation agent, was tested at 600–2000 mM concentration
and applied as a positive control [42]. Triton X-100 detergent was
used at 10 mg/ml concentration in viability assays as a reference
compound to cause cell death.
Real-Time Monitoring of Impedance
Impedance-based cell electronic sensing is a label-free technique
for dynamic monitoring of living cells. The RTCA-SP instrument
(ACEA Biosciences, Inc., USA) utilizes an automatical and
continuous impedance measurement to non-invasively quantify
adherent cell proliferation and viability in real-time. This method
has been succesfully used to measure number, adherence, growth
and health of cells in control and treatment conditions [43–46]. E-
plates were coated with rat tail collagen at room temperature and
dried for 40 min under UV and air-flow. Culture medium (50 mL)
was added to each well for background readings, then 50 mL of
cell suspension was dispensed at the density of 1.66104 cells/well.
The cells were kept in incubator at 37uC for 5 days until reaching
confluence. Impedance was monitored every 2 minutes. The cell
index at each time point was defined as (Rn - Rb)/15, where Rn is
the cell-electrode impedance of the well when it contains cells and
Rb is the background impedance of the well with the medium
alone.
MTT Dye Reduction Cell Viability Assay
Living cells convert the yellow dye 3-(4,5-dimethyltiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) to purple, insoluble
formazan crystals. Decrease in dye conversation reflects cellular
damage. Human endothelial hCEMC/D3 cells grown to con-
fluency in 96-well culture plates were treated with methylglyoxal
with or without protective agents for 8 hours. Then the treatment
medium was removed from the wells and the cells were incubated
with MTT solution (0.5 mg/mL) in Dulbecco’s modified Eagle’s
medium for 3 hours in CO2 incubator. The amount of formazan
crystals was dissolved in dimethyl-sulfoxide and determined by
measuring absorbance at 570 nm wavelength with a microplate
reader (Fluostar Optima, BMG Labtechnologies, Germany). Cells
receiving treatment medium without methylglyoxal or protective
agents, the control group, was considered as 100% viable.
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Detection of Reactive Oxygen Species
To measure reactive oxygen species (ROS) we used a
fluorometric detection probe, chloromethyl-dichloro-dihydro-fluo-
rescein diacetate (DCFDA) (Molecular Probes, Life Technologies
Corp., Carlsbad, USA). This indicator penetrates the cells by
diffusion and becomes deacetylated by intracellular esterases.
Oxidation of DCFDA by reactive oxygen species yields a
fluorescent molecule. Confluent brain endothelial cell layers
cultured in 96-well plates were pretreated with methylglyoxal
(600 mM) and/or protective agents for 0–8 hours, then washed,
and incubated with Ringer–Hepes buffer containing 2 mM
DCFDA and 1.5 mM pluronic acid (Life Technologies, Molecular
Probes, USA) for 1 hour at 37uC. Hydrogen peroxide pretreat-
ment (100 mM, 30 min) served as a positive control in the ROS
assay. The plates were measured by Fluostar Optima fluorescent
plate reader (BMG Labtechnologies, Germany) at 485 nm
excitation and 520 nm emission wavelengths. The fluorescent
values were presented as percent of the control group (cells
receiving treatment medium without methylglyoxal or protective
agents) after 1 hour incubation with DCFDA indicator.
Measurement of Barrier Functions: Transendothelial
Electrical Resistance
Transendothelial electrical resistance (TEER) reflects the
permeability of intercellular tight junctions for ions. TEER was
measured by an EVOM resistance meter using STX-2 electrodes
(World Precision Instruments Inc., Sarasota, FL, USA) and
expressed relative to the surface area (V6cm2). TEER values of
cell-free inserts were subtracted from the measured data. The
TEER of untreated human hCMEC/D3 brain endothelial cell
monolayers was 43.366.1 V6cm2 (mean 6 SD; n= 60) in
agreement with literature data [40]. Resistance measurements
were carried out before and after treatments to check the barrier
integrity. The TEER values are presented as percent of non
treated control groups.
Measurement of Barrier Functions: Permeability
Experiments
To measure the flux of permeability marker molecules
fluorescein isothiocyanate labeled dextran (FITC-dextran, mw:
4.4 kDa) and Evans blue-labeled albumin (mw: 67 kDa) across
endothelial cell layers hCMEC/D3 cells were seeded onto
Transwell inserts and grown for 5 days. Inserts with confluent
layers were transferred to 12-well plates containing 1.5 mL
Ringer–Hepes solution (118 mM NaCl, 4.8 mM KCl, 2.5 mM
CaCl2, 1.2 mM MgSO4, 5.5 mM D-glucose, 20 mM Hepes,
pH 7.4), which was the abluminal (lower) compartment in the
permeability experiments. In the upper chambers (luminal
compartment) culture medium was replaced by 500 mL of
Ringer-Hepes buffer containing 100 mg/mL FITC-dextran solu-
tion and 165 mg/mL Evans blue bound to 0.1% BSA. The plates
were kept in a 37uC incubator with 5% CO2 on a horizontal
shaker (100 rpm) for 1 h. After incubation the concentrations of
the marker molecules in samples from the luminal (upper) and
abluminal (lower) compartments were determined by a fluorescent
microplate reader (Fluostar Optima; emission wavelength:
485 nm, excitation wavelength: 520 nm). Flux across cell-free
inserts was also measured.
The apparent permeability coefficient (Papp) was calculated
from the concentration difference of the tracer in the abluminal
compartments (D[C]A) after 1 hour and luminal compartments at
0 hour ([C]L), the volume of the abluminal compartment (VA;
1.5 mL) and the surface area available for permeability (A;
1.1 cm2) by the following equation [47].
Papp(cm=s)~
D C½ A|VA
A| C½ L|Dt
The Papp values were presented as percent of non treated
control groups.
Immunohistochemistry
Cell-cell connections and morphology of hCMEC/D3 cells
were confirmed by immunostaining for junctional proteins b-
catenin and claudin-5. Cells cultured on rat tail collagen coated
Transwell inserts were washed in phosphate buffered saline (PBS)
and fixed with acetone-methanol (1:1) for b-catenin and with
ethanol-acetic acid (95:5) for claudin-5 at 220uC for 10 minutes.
After rehydrating with PBS containing 1% fetal bovine serum and
washing with PBS cells were blocked with 3% BSA in PBS at room
temperature for 30 minutes. Samples were incubated overnight at
4uC with anti-b-catenin or anti-claudin-5 primary antibodies
(Invitrogen, Life Technologies Corp., Carlsbad, USA; 1:200).
Incubation with Cy3-labeled or Alexa Fluoro 488-labeled anti-
rabbit IgG secondary antibodies and bis-benzimide (Hoechst dye
33342) to stain cell nuclei lasted for 1 hour. Between and after
incubations cells were washed three times with PBS. Inserts were
mounted in Gel Mount (Biomeda, USA) and staining was
examined by Olympus Fluoview FV1000 and Leica SP5 confocal
laser scanning microscopes (Leica Microsystems GmbH, Wetzlar,
Germany).
Holographic Phase Contrast Microscopy
Digital holographic images were taken with a Holo-Monitor M3
instrument (Phase Holographic Imaging AB, Lund, Sweden).
Endothelial cells were cultured on collagen coated culture dishes
with borosilicate glass bottom (MatTek, Ashland, MA, USA). All
treatments lasted for 4 hours. Holographic images of the same
culture area were captured before and during treatments. Cell
morphological changes were analysed by the Holostudio 2.4
software provided with the microscope (Phase Holographic
Imaging AB, Lund, Sweden). Each point in the box plot reflects
the data obtained on a single cell [48,49].
Statistical Analysis
All data presented are means 6 SD or SEM as indicated in the
text. The values were compared using the analysis of variance
followed by Dunnett or Bonferroni posthoc tests using GraphPad
Prism 5.0 software (GraphPad Software Inc., San Diego, CA,
USA). Changes were considered statistically significant at p,0.05.
All experiments were repeated at least three times, the number of
parallel wells or inserts for each treatment and time point varied
between 3 and 16.
Results
Methylglyoxal-induced Time- and Dose-dependent
Cellular Toxicity Measured by Real-Time Impedance
Monitoring
The direct effect of methylglyoxal on cellular changes and cell
viability was investigated by real-time impedance monitoring with
an RTCA-SP instrument. Methylglyoxal showed dose and time-
dependent toxicity in hCMEC/D3 endothelial cells (Figure 1A).
The highest concentrations of methylglyoxal (300–1000 mM)
caused a very quick and significant decrease of cell index values
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compared to control. However, this initial impedance drop was
compensated with time depending on the amount of methylgly-
oxal. In case of cells treated with 100–400 mM methylglyoxal no
effect on cell index was measured from 3 to 24 hour. A significant
toxicity of methylglyoxal was seen in concentrations of 500 mM
and above. Irreversible cell damage was observed at 800 and
1000 mM (Figure 1A).
To validate our data, 600 mM methylglyoxal concentration was
tested using the colorimetric end-point MTT assay at 8-hour time
point. The cell viability values after methylglyoxal treatment
measured by the MTT test decreased to 56.764.6% (mean 6 SD,
n= 50) in good agreement with the decrease of cell index at the
same concentration of methylglyoxal at the same time point
(58.265.8%, mean 6 SD, n= 10). The 600 mM concentration of
methylglyoxal causing approximately 50% toxicity was selected for
further tests.
To support the relevance of our data on endothelial cell line, the
effect of methylglyoxal was also tested on cultures of primary rat
brain endothelial cells (for preparation of cultures see Text S1).
The toxicity of methylglyoxal was investigated by the WST-8
colorimetric assay of cell metabolism and LDH release reflecting
cell membrane damage. No effect on viability was measured in
primary cells treated with 100–300 mM methylglyoxal compared
to control. Toxic effect was seen at 500 mM: the cell viability
values decreased to 68.0615.5% of the control (mean 6 SEM,
n=8) by WST-8 assay and 76.765.9% (mean 6 SEM, n= 12) by
LDH assay (Figure S2).
Co-administration of Edaravone Protects against
Methylglyoxal-Induced Toxicity Measured by Real-Time
Impedance Monitoring
To investigate the protective effects of edaravone on methyl-
glyoxal-induced cell injury, brain endothelial cells were co-treated
with different concentrations of edaravone and with a fixed
concentration of methylglyoxal (600 mM). Cell index decreased by
half in the methylglyoxal group (Figure 1B). Edaravone protected
cells at 1000–3000 mM concentrations and reversed or attenuated
the drop in cell index caused by methylglyoxal in a dose and time-
dependent way. In case of cells co-treated with 60–600 mM
edaravone no effect on cell index was measured compared to the
methylglyoxal group. Edaravone at 1 mM showed a short term
(0.5–2 hour) but statistically significant effect. The 1.5 and 2 mM
concentrations of edaravone could protect the endothelial cells till
6 and 8 hours post-treatment, respectively. Long lasting protection
of hCMEC/D3 cells could be observed at 2.5 and 3 mM
concentrations of edaravone.
Our reference compound, aminoguanidine at 2 mM concen-
tration showed a complete protection against methylglyoxal-
induced cellular toxicity (Figure 1B). This result is in agreement
with its effect determined by MTT test. Aminoguanidine at 2 mM
concentration was found to be the most effective against
methylglyoxal-induced cell damage in the colorimetric assay: cell
viability was 93.260.6% of control at 8 hour time point. To
determine the effect of protective agents alone, cells were
incubated with different concentrations of edaravone (600–
3000 mM) and aminoguanidine (600–2000 mM). There was no
statistically significant decrease in cell viability measured by MTT
assay and impedance monitoring in cells treated with edaravone or
aminoguanidine alone. (Figure S1). Edaravone at 3 mM concen-
tration increased both the impedance of the endothelial layers and
the metabolic activity measured by MTT assay (121.865.9%,
mean 6 SD, n= 4, p,0.05).
Based on these results, the 3 mM concentration of edaravone
showing the best protection of brain endothelial cells was selected
for other investigation.
Methylglyoxal-induced Time-Dependent ROS Production
As methylglyoxal generates not just carbonyl [18] but also
oxidative stress [23,24], ROS production in cells treated with
600 mM methylglyoxal was investigated at different time points
(Figure 2A). The fluorescence intensity in cultured human brain
endothelial cells measured by DCFDA assay at 1 hour time point
was considered as 100% (1285.66105.2, fluorescence intensity in
arbitrary units). ROS production was significantly enhanced
(126.1612.0%, p,0.001) after one hour treatment by methylgly-
oxal as compared to control group, and remained elevated
(114.7614.9% and 114.469.7%) at 2 and 4 hours time points,
respectively. ROS production in endothelial cells treated for 8
hours by methylglyoxal (109.765.7%) did not differ significantly
from non-treated group. Hydrogen peroxide treatment (100 mM,
15 min), a positive control in the ROS assay, elevated the amount
of ROS measured in brain endothelial cells by 2 fold
(199.467.1%; Figure 2A). Based on these data and results from
real-time monitoring, the 4 hours time point of 600 mM
methylglyoxal treatment causing significantly elevated ROS
production was chosen for further experiments.
Co-administration of Edaravone Protects against
Methylglyoxal-induced ROS Production
Edaravone (3 mM) completely inhibited the methylglyoxal-
induced increase in ROS production (120.967.3%,) bringing back
to the level of control (97.261.7%, p,0.001 as compared to the
methylglyoxal treated group) at the 4 hours time point. Co-
administration of aminoguanidine (2 mM) also decreased ROS
production stimulated by methylglyoxal (89.162.1%). In contrast
to edaravone, which had no effect alone (102.561.7%), treatment
with aminoguanidine alone decreased the amount of ROS in
endothelial cells below the level of the control group (87.461.3%;
Figure 2B).
Methylglyoxal-Induced Decrease of Resistance
The direct effect of different concentrations of methylglyoxal on
the ionic permeability of brain endothelial monolayers was
determined by TEER measurement. The resistance of hCMEC/
D3 control group was 37.565.5 V6cm2 (mean 6 SD; n= 14).
Methylglyoxal at 100 and 300 mM concentrations (4 hours) did
not cause significant changes. Treatment of endothelial cell
monolayers with methylglyoxal at 600 mM and 1 mM concentra-
tions significantly impaired the barrier integrity and decreased
TEER to 90.662.5% and 89.962.7% (p,0.01 for both treatment
groups) compared to control (Figure 3A). Treatment of primary
brain endothelial cells with methylglyoxal at 300 and 500 mM
concentrations also damaged the integrity of the barrier (Figure
S3A). Methylglyoxal at 300 and 500 mM concentrations decreased
the resistance (80.264.9% and 56.864.6%, respectively) as
compared to the control (96.1611.4%; n= 14).
Co-administration of Edaravone Protects against
Methylglyoxal-Induced Resistance Decrease
Co-administration of the protective agents with methylglyoxal
preserved the barrier tightness and elevated resistance values to
the level of control (edaravone: 97.960.8%; aminoguanidine:
99.262.1%). There was no significant difference between the
resistance value of control and the groups treated with edaravone
(3 mM) or aminoguanidine (2 mM) alone (Figure 3B).
Edaravone Protects Brain Endothelial Barrier
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Figure 1. Effect of methylglyoxal and edaravone on cell viability. Effect of methylglyoxal (100–1000 mM) on human hCMEC/D3 endothelial
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Methylglyoxal-Induced Dose-Dependent Permeability
Increase
Following the real-time impedance monitoring experiments, the
direct effect of different methylglyoxal concentrations on the
permeability of brain endothelial monolayers was measured using
dextran (Figure 4A) and albumin (Figure 4B) as marker molecules.
Cells were incubated with methylglyoxal (100–1000 mM, 4 hours),
then permeability measurements were performed. Methylglyoxal
at 100 and 300 mM concentrations did not cause barrier
disruption. Treatment of hCMEC/D3 endothelial cell monolayers
with methylglyoxal at 600 mM and 1 mM concentrations signif-
icantly impaired the barrier integrity and increased the perme-
ability for both markers. The flux of the paracellular marker
4.4 kDa FITC-dextran was elevated by 1.5 fold (158.965.8%) in
monolayers treated with 600 mM methylglyoxal and was doubled
(196.467.2%) by 1 mM methylglyoxal treatment as compared to
the control group (Figure 3A). The permeability coefficient values
for transcellular permeability marker albumin (67 kDa) were one
sixth of the values for FITC-dextran (4.4. kDa),
0.660.036106 cm/s and 3.660.86106 cm/s, respectively, in
agreement with literature data [39]. The permeability for albumin
was doubled (221.868.7%) after incubation with 600 mM
methylglyoxal and tripled (307.268.1%) in the case of 1 mM
methylglyoxal treatment (Figure 4B). Treatment of primary brain
endothelial cells with 500 mM methylglyoxal also increased the
permeability of monolayers for fluorescein (209.69617.7%) and
albumin (168.9638.6%), but 100–300 mM concentrations had no
effect (Figure S3B and S3C).
These results, that low concentrations of methylglyoxal (100–
300 mM) do not increase permeability, while higher concentra-
tions significantly reduce barrier integrity are in agreement with
our results from impedance measurements. In further permeability
assays to test the effect of protective agents, human brain
endothelial cells were treated with 600 mM concentration of
methylglyoxal.
Co-administration of Edaravone Protects against
Methylglyoxal-Induced Permeability Increase
Co-administration of edaravone at 3 mM concentration,
selected previously by impedance measurement, could completely
protect brain endothelial monolayers from the damaging effects of
methylglyoxal (Figure 4C and 4D). Co-administration of edar-
avone shielded the cells from the damaging effect of methylglyoxal
and kept the permeability for FITC-dextran at the control level
(MG+E: 103.864.9% vs. MG: 165.666.0%). The same effect was
seen by the co-administration of aminoguanidine at 2 mM
concentration, endothelial permeability stayed at the level of
control group (100.661.7%) (Figure 4C). The increased perme-
ability for albumin of brain endothelial cell layers treated with
methylglyoxal (261.3612.2%) was completely prevented by the
co-administration of 3 mM edaravone (112.162.8%) or 2 mM
aminoguanidine (113.066.5%) (Figure 4D).
Aminoguanidine (2 mM) alone had no effect on the permeabil-
ity of brain endothelial monolayers. Edaravone (3 mM) was able
to tighten the barrier for both FITC-dextran (81.962.0%;
Figure 4C) and albumin (56.563.5%; Figure 4D) as compared
to the permeability of the control group.
Co-administration of Edaravone Protects against
Methylglyoxal-Induced Changes in Immunostaining
The effect of methylglyoxal on cell-cell adhesion was investi-
gated by immunostaining for b-catenin, a cytoplasmic adherens
junction protein, and claudin-5, a transmembrane tight junction
protein (Figure 5). In control monolayers b-catenin staining was
localized to the cell border and the tightly apposed, elongated
endothelial cells were well delineated (Figure 5A). Claudin-5
localization at the interendothelial junctions was less stringent than
for b-catenin but clearly visible in part of the cell borders
(Figure 5E) and resembled the immunostaining shown in the paper
describing this cell line [39]. The pattern of the staining was
dramatically changed in methylglyoxal (600 mM, 4 hours) treated
cells. Treatment with methylglyoxal resulted in decreased immu-
nostaining intensity, fragmentation or loss of the continuous
cortical staining pattern, the appearance of intercellular gaps
(Figure 5B and 5F) and apoptotic cells (Figure 5F). Co-
administration of protective agents, edaravone (Figure 5C and
5G) and aminoguanidine (Figure 5D and 5H) attenuated these
changes, the monolayer integrity was better preserved and the
immunostaining pattern resembled to the control ones.
Co-administration of Edaravone Protects against
Methylglyoxal-Induced Morphological Changes
Examined by Holographic Phase Contrast Microscopy
Holographic phase contrast microscopic analysis was performed
to visualize the morphological changes caused by methylglyoxal
and the protective effect of edaravone (Figure 6). This novel
technology enabled us to follow living cells in a label-free and non-
invasive way. Morphological parameters of treated cells, such as
surface area, optical thickness and cell volume could be measured.
Holographic images were taken every 30 minutes before and
during the 4-hour treatment of hCMEC/D3 cells. Endothelial
cells show a flat, elongated shape and grow next to each other.
Treatment with methylglyoxal caused drastic changes in cell
morphology: as indicated by the colour-scale, growth of cell height
was especially prominent (Figure 6). In contrast, in endothelial
cells co-treated with edaravone (3 mM) and methylglyoxal
(600 mM) there was no change in cell morphology during the
treatment period (Figure 6). Two short videos on the cell
morphology in both treatment groups at all timepoints are shown
as supplementary data (Video S1 and S2). The analysis of
morphological data is shown on Figure 7. During treatment with
methylglyoxal the area of the cells significantly decreased
(63.1633.7%) and their optical thickness increased by 1.8 fold
(176.2636.1%) compared to the values at the beginning of
treatment. These data indicate that endothelial cells treated with
methylglyoxal contracted and rounded up, which is also visible on
Figures 6 and Video S1. The volume of the cells was unchanged.
Meanwhile, no changes were observed in cells co-treated with
edaravone and methylglyoxal (Figure 7) or in the control group
which was treated with medium only. This is the first report on
methylglyoxal-induced morphology changes in brain endothelial
cells using holographic phase contrast imaging.
cells measured by real-time cell electronic sensing method (A). Effect of co-treament with 600 mM methylglyoxal and different concentrations of
edaravone (MG + E; 600–3000 mM) or aminoguanidine (MG + AG; 2 mM) (B). Cell index is expressed as an arbitrary unit and calculated from
impedance measurements between cells and sensors. Data are presented as means 6 SD, n = 10. Triton X-100 was used at 10 mg/mL concentration.
Statistical analysis: two-way ANOVA followed by Bonferroni test. Statistically significant differences (p,0.05) from the control group (#) and from the
methylglyoxal-treated group (*) are indicated.
doi:10.1371/journal.pone.0100152.g001
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Discussion
Carbonyl stress and brain endothelial damage
Higher incidence of stroke, dementia and Alzheimer’s disease is
observed in diabetes mellitus [50,51]. Carbonyl stress induced by
high level of methylglyoxal is responsible for the diabetes related
vascular complications [52]. A direct toxic effect of methylglyoxal
on brain microvessels was proposed in a recent study [28]. In the
present study we further supported the fact that methylglyoxal
alone could induce damage to brain endothelial cells. Methylgly-
oxal exerted a time- and dose-dependent toxicity on cultured
human brain endothelial cells; it significantly reduced the integrity
of the barrier measured by both functional and morphological
experiments. This is the first study to provide kinetic data on the
toxicity of methylglyoxal by impedance-based cell electronic
sensing, a noninvasive label-free technique. The two different cell
viability assays we used were in complete agreement on the direct
cellular damaging effect of methylglyoxal, impedance data
reflecting changes in cell adhesion, cell shape and number were
confirmed by MTT tests measuring the metabolic activity of cells.
Our data lend support to and expand previous findings on the
effect of methylglyoxal on human brain endothelial cells
[25,28,37,53]. We selected the human hCMEC/D3 cell line as
a simplified model of the blood-brain barrier. This cell line is
widely used in different experiments, including pharmacological
and drug studies [40]. To support the relevance of our data on
hCMEC/D3 endothelial cell line, the effect of methylglyoxal was
also tested on primary cultures of rat brain endothelial cells. The
observed effects were in agreement with our observations on the
human cell line, indicating a similar sensitivity of primary
endothelial cells and hCMEC/D3 endothelial cell line for the
toxic effects of methylglyoxal. We found no data on primary brain
endothelial cells related to methylglyoxal in the literature,
therefore the present observation is the first study to include
primary brain endothelial cells in this setting. The relevance of our
findings on endothelial cells is limited by the use of high
concentrations of methylglyoxal to induce barrier damage, a
common concern in cell culture studies. However, in four recent
and independent studies both the time needed to measure
methylglyoxal-induced injury in cultured endothelial cells and
the concentrations used were in similar range as in our study
[25,28,37,53].
Damage by methylglyoxal is mediated not only via carbonyl
stress, but also by oxidative stress. [23,24]. Reactive oxygen species
are generated as by-products of protein glycation [54]. Further-
more, methylglyoxal increases glycation of selected mitochondrial
proteins resulting in increased formation of superoxide [55].
Elevated level of ROS weakens the barrier integrity [56], however
the contribution of methylglyoxal-triggered ROS production in
the increased endothelial permeability is controversial [28]. In the
present study we confirmed that methylglyoxal treatment
promotes oxidative stress in brain endothelial cells, similarly to
previous studies on endothelial cells [28,53] and other cellular
systems [57]. The kinetics of ROS production also helped to
determine the optimal time point for protection assays and other
experiments: a time point, where ROS formation was still
elevated, was purposefully selected.
In good agreement with the data from toxicity measurements
methylglyoxal increased the permeability of human and rat brain
endothelial monolayers. The effect was dose-dependent, with only
high concentrations of methylglyoxal causing significant damage
in barrier integrity. These data are in accordance with findings of a
previous study showing that methylglyoxal induced permeability
increase in brain endothelial cells [28]. In that study decreased
transendothelial electrical resistance and increased dextran flux
were coupled with glycation of occludin and disturbed localization
of zonula occludens-1 tight junction proteins [28]. In the present
study we found the redistribution of two other junctional proteins
important for the regulation of brain endothelial permeability,
namely the tight junction protein claudin-5 and adherens
junctional protein b-catenin in methylglyoxal-treated brain
endothelial cells. Claudin-5 is the most abundant integral
membrane protein of the brain endothelial tight junctions and a
major regulator of the blood-brain barrier permeability [59]. b-
catenin binds the cytoplasmic tail of vascular endothelial cadherin
(VE-cadherin) to the actin cytoskeleton [58]. Besides its role as a
cytoskeletal linker, b-catenin is an important signaling and
transcriptional factor at the blood-brain barrier regulating its
tightness [59]. Delocalization/redistribution of b-catenin in brain
endothelial cells is linked to permeability increase in many
pathologies [60,61,62]. We demonstrated for the first time, that
treatment with methylglyoxal resulted in fragmentation and loss of
the continuous cortical pattern of b-catenin in brain endothelial
cells, confirming the importance of b-catenin in barrier integrity.
For the maintenance of the integrity of the blood-brain
permeability barrier the attachment of endothelial cells to the
basement membrane is crucial [63]. Damage to the basal lamina
weakens microvascular wall structures and results in increase of
brain vessel permeability in vivo [64]. Our data confirmed these
observations and visualized for the first time the kinetics of
morphological changes caused by methylglyoxal using a novel
technique, holographic phase contrast microscopy. This technol-
ogy follows the morphology of living cells in a label-free and non-
invasive way and detects only the effects of the tested compound
[48,49]. In our study methylglyoxal changed drastically the shape
of brain endothelial cells by time: the area of cells decreased, their
optical height significantly increased indicating cell-cell and cell-
basal lamina detachment. Similar observation was made in case of
peripheral endothelial cells, where modification of basement
membrane by methylglyoxal caused cell detachment, anoikis and
inhibition of angiogensis [65].
Protective effect of edaravone on methylglyoxal-injured
brain endothelial cells
Edaravone was reported to protect brain microvessels and the
blood-brain barrier after ischemic stroke [33,34]. In a recent
study, edaravone reduced cell injury in oxygen-glucose deprivation
in vitro model. Edaravone pretreatment attenuated methylglyox-
al-induced decrease in cell viability of brain endothelial cells [37].
In our study co-treatment with edaravone provided a complete
protection against the toxic effect of methylglyoxal. We could see a
dose- and time-dependent effect based on kinetic data from
impedance measurements. Our data are in agreement with
viability studies on the effect of edaravone pretreatment against
Figure 2. Effect of methylglyoxal and edaravone on reactive oxygen species production. Time-dependent effect of methylglyoxal (MG;
600 mM) on ROS production of human brain endothelial cells (hCMEC/D3) (A). Effect of co-treament with 600 mMmethylglyoxal and 3 mM edaravone
(MG + E) or 2 mM aminoguanidine (MG + AG) after 4 hours (B). Fluorescent intensity of ROS expressed as a percentage of control (C). Values
presented are means 6 SD, n = 9. Statistical analysis: ANOVA followed by Dunnett test. Statistically significant differences (p,0.05) from the control
group (#) and from the methylglyoxal-treated group (*) are indicated.
doi:10.1371/journal.pone.0100152.g002
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methylglyoxal-induced toxicity [37]. Edaravone treatment alone
increased the metabolic activity and impedance of the endothelial
layers. A beneficial effect of edaravone on human endothelial cells
was also found previously by resistance measurement and
proteomic assay [35,36]. The edaravone concentrations used were
in the millimolar range similarly to another independent work on
cultured human brain endothelial cells. For long-lasting protection
suprapharmacological concentration of edaravone [66] was
needed in our culture study. However, the applied methylglyoxal
levels were also comparably high, as in other in vitro methylgly-
oxal studies [25,28,37,53]. Although we use higher concentrations
in cultured cells, importantly, the ratio of the methylglyoxal to
edaravone used in our study is the same as the ratio of the
pathological plasma methylglyoxal concentrations [67] to clinical
concentrations of edaravone [66].
Originally, edaravone has been described as a drug to treat
ischemic stroke by protecting against oxidative stress [31]. Its
antioxidant effect was observed in our experiment, too. In a recent
independent study edaravone suppressed methyglyoxal-induced
ROS production in human brain endothelial cells by two possible
mechanisms [37]. Pre-treatment with edaravone decreased meth-
ylglyoxal-induced AGE accumulation and activation of its
receptor RAGE [37], and the subsequent production of ROS
[68,69]. Furthermore, edaravone inhibited protein-glycation by
Figure 3. Effect of methylglyoxal and edaravone on the resistance of human brain endothelial monolayers. The effect of methylglyoxal
on the resistance of human brain endothelial cells (hCMEC/D3) after 4-hours treatment (A). Protective effect of 3 mM edaravone (MG + E;) and 2 mM
aminoguanidine (MG + AG) on methylglyoxal (MG, 600 mM) induced changes in the resistance of cell layers (4 hours co-treatment), and effect of
3 mM edaravone (E) and 2 mM aminoguanidine (AG) alone (B). TEER values are expressed as percentage of control (C). Values presented are means6
SD, n = 4. Statistical analysis: ANOVA followed by Dunnett test. Statistically significant differences (p,0.05) from the control group (#) and from the
methylglyoxal treated group (*) are indicated.
doi:10.1371/journal.pone.0100152.g003
Figure 4. Effect of methylglyoxal and edaravone on the permeability of human brain endothelial monolayers. Dose-dependent effect
of methylglyoxal-induced changes in the permeability of human brain endothelial cells (hCMEC/D3) for FITC-dextran (4.4 kDa) (A) and Evans blue
labelled albumin (65 kDa) after 4 hours treatment (B). Protective effect of 3 mM edaravone (MG + E;) and 2 mM aminoguanidine (MG + AG) on
methylglyoxal-induced (MG, 600 mM) changes in the permeability for FITC-dextran (4.4 kDa) (C) and Evans blue labelled albumin (D), when co-treated
for 4 hours. Effect of 3 mM edaravone (E) and 2 mM aminoguanidine (AG) alone (C, D). Papp, apparent permeability coefficient expressed as a
percentage of control (C). Values presented are means 6 SD, n = 4. Statistical analysis: ANOVA followed by Dunnett test. Statistically significant
differences (p,0.05) from the control group (#) and from the methylglyoxal treated group (*) are indicated.
doi:10.1371/journal.pone.0100152.g004
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methylglyoxal in a cell free system [37], therefore, it decreased
ROS generated as by-products during protein glycation [54]. All
these results together indicate that the antioxidant mechanisms
induced by edaravone contribute to its protective effect against
methylglyoxal-induced oxidative stress.
Prior work described, that edaravone protects from methylgly-
oxal-induced injury by inhibiting AGEs/RAGE/oxidative stress in
Figure 5. Effect of methylglyoxal and edaravone on junctional morphology. Immunostaining for adherens junction protein b-catenin (A–D)
and integral tight junction membrane protein claudin-5 (E–H) in human hCMEC/D3 brain endothelial cells. Control (A and E), 4 hour treatment with
methylglyoxal (600 mM; B and F), co-treatment with edaravone (3 mM; C and G) or aminoguanidine (2 mM; D and H). Blue color: bis-benzimide
staining of cell nuclei; red color: immunostaining for b-catenin; green color: immunostaining for claudin-5. Bar = 20 mm.
doi:10.1371/journal.pone.0100152.g005
Figure 6. Effect of methylglyoxal and edaravone on cellular morphology. Holographic phase contrast images of morphological alterations
induced in hCMEC/D3 human brain endothelial cells by treatment with methylglyoxal (MG; 600 mM) and co-treatment with 3 mM edaravone (MG + E)
for 4 hours. Color scale bar correspond to the height of single cells. Data were analysed by means of HoloStudio 2.4 software. Red circles indicate cells
with drastical changes in cell morphology. Yellow circles indicate cells without any morphological changes. Bar = 100 mm.
doi:10.1371/journal.pone.0100152.g006
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human brain microvascular endothelial cells [37]. However, it
remained unanswered whether edaravone can also protect against
methylglyoxal-induced barrier dysfunction in brain endothelial
monolayers. Therefore, this study focused on the protective effect
of edaravone against methylglyoxal-induced barrier damage. We
found that co-treatment with edaravone restored barrier proper-
ties of endothelial cells and protected against methylglyoxal-
induced decrease of resistance and increase in permeability for
paracellular and transcellular markers. Moreover, we also
demonstrated that edaravone treatment alone tightened the brain
endothelial barrier. Our data expand and further support previous
observations on barrier enhancing effect of edaravone [35,36].
Increased endothelial permeability was coupled with disturbed
localization of junctional proteins claudin-5 and b-catenin after
incubation with methylglyoxal, while co-treatment with edaravone
restored distribution of both proteins along the cell borders.
Similar observation was made in a previous study, where
edaravone treatment enhanced b-catenin at cell-cell contact area
and the cortical arrangement for its linked protein, actin on half
confluent endothelial monolayer [35]. Our holographic phase
contrast microscopic data are in accordance with these observa-
tions: edaravone completely prevented methylglyoxal-induced
changes in cell morphology, no sign of detachment and cellular
morphological change was observed, indicating there was no
cytoskeletal rearrangement.
Our results have answered the question that edaravone can
protect against methylglyoxal-induced barrier dysfunction in brain
endothelial cells. However, the underlying signal transduction
pathways during co-treatment were not examined and further
work is needed to elucidate the precise mechanism.
Conclusion
This is the first study to investigate the protection of cerebral
endothelial cells by edaravone in co-treatment with methylglyoxal.
Our results provide compelling evidence for barrier protective
effect of edaravone in cultured endothelium of brain microvascu-
lature. Data from this study could have therapeutical implication
for disorders and diseases that are associated with carbonyl stress.
Figure 7. Effect of methylglyoxal and edaravone on area and thickness of adjacent cells. Morphological alterations induced in human
brain endothelial cells (hCMEC/D3) by treatment with methylglyoxal at 600 mM (A and B) and co-treatment with edaravone at 3 mM (C and D) for 4
hours. Surface area (A and C) and average optical thickness (B and D) were calculated before and during treatments. Box represents 25 and 75
percentiles. Horizontal line represent the median. Whiskers show minimum and maximum values. Statistical analysis: ANOVA followed by Dunnett
test, n = 12. Statistically significant differences (p,0.05) from 0 time point (*) are indicated.
doi:10.1371/journal.pone.0100152.g007
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Supporting Information
Figure S1 Effect of edaravone and aminoguanidine on
cell viability. Effect of edaravone (E; 600 mM–3 mM) and
aminoguanidine (AG; 600 mM–2 mM) on human hCMEC/D3
endothelial cells measured by real-time cell electronic sensing
(RTCA-SP) method (A) and by MTT metabolic assay at 8 hours
timepoint (B). MTT assay and cell index data are expressed as
percentage of control. Data are presented as means 6 SD, n= 6.
Triton X-100 was used at 10 mg/mL concentration. Statistical
analysis: ANOVA followed by Dunnett or by Bonferroni test.
Statistically significant differences (p,0.001) from the control
group (#) are indicated.
(TIF)
Figure S2 Effect of methylglyoxal on the viability of
primary brain endothelial cells. Effect of methylglyoxal
(100–1000 mM) on primary rat brain endothelial cells measured
by WST-8 (A) and lactate dehydrogenase (LDH) release assay (B).
Values are expressed as percentage of control. Data are presented
as means 6 SEM, n=20. Statistical analysis: one-way ANOVA
followed by Dunett test. Statistically significant differences (p,
0.05) from the control (C) group (#) are indicated.
(TIF)
Figure S3 Effect of methylglyoxal on the barrier prop-
erties of primary brain endothelial monolayers. Dose-
dependent effect of methylglyoxal-induced changes in the
resistance (A) and the permeability of primary rat brain endothelial
cells for sodium-fluorescein (B) and Evans blue labeled albumin
(B). Transendothelial electrical resistance (TEER) and endothelial
permeability coefficient (Pe) are expressed as a percentage of
control (C). Data presented are means 6 SEM, n= 16–24.
Statistical analysis: ANOVA followed by Dunnett test. Statistically
significant differences (p,0.05) from the control group (#) and
from the methylglyoxal treated group (*) are indicated.
(TIF)
Text S1 Materials and Methods for figures S2 and S3.
(DOC)
Video S1 Effect of methylglyoxal on cellular morpholo-
gy. Videos were made from holographic phase contrast images on
morphological alterations induced in hCMEC/D3 human brain
endothelial cells by treatment with 600 mM methylglyoxal (Video
S1) and co-treatment with 3 mM edaravone (Video S2). Pictures
were taken every 30 min until 4 hours. Color scale bar correspond
to the height of single cells. Data were analysed by means of
HoloStudio 2.4 software.
(AVI)
Video S2 Effect of methylglyoxal on cellular morpholo-
gy. Videos were made from holographic phase contrast images on
morphological alterations induced in hCMEC/D3 human brain
endothelial cells by treatment with 600 mM methylglyoxal (Video
S1) and co-treatment with 3 mM edaravone (Video S2). Pictures
were taken every 30 min until 4 hours. Color scale bar correspond
to the height of single cells. Data were analysed by means of
HoloStudio 2.4 software.
(AVI)
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